Date: 2015-11-10
Type of information: IPO
Company: Curetis (Germany)
Investors:
Amount: € 40 million
Funding type: IPO
Planned used:
Others: * On November 10, 2015, Curetis, a developer of next-level molecular diagnostic solutions, announced the completion of its initial public offering, which was launched on October 28, 2015. The listing of and first trading of all of Curetis\' shares on Euronext in Amsterdam and Euronext in Brussels is expected to commence on November 11, 2015 under the ticker symbol \"CURE\". The final offer price for the Offering is set at € 10.00 (the \"Offer Price\"), corresponding to market capitalization of the Company at listing of approximately € 151 million (prior to the exercise of the Over-allotment Option). Total number of ordinary Shares issued in the Offering amounts to 4,000,000 new shares (representing approximately 26.5% of the Shares, prior to the exercise of the Over-allotment Option). In addition, an Over-allotment Option to subscribe to up to 600,000 additional newly issued Shares, equivalent to up to 15% of the total number of the New Shares) at the Offer Price has been granted by the Company to RBC Capital Markets, as Sole Global Coordinator, on behalf of the Underwriters. The Over-allotment Option will be exercisable for a period of 30 calendar days following the First Trading Date. If the Over-allotment Option is exercised in full, the total number of Offer Shares will represent approximately 29.3% of the Shares and the approximate market capitalization of Curetis will be € 157 million (at the Offer Price). The Company will announce if and when the Over-allotment Option is exercised. Delivery of the Offer Shares, closing and settlement of the Offering and the start of unconditional trading in the Shares are expected to take place on November 13, 2015. The Offering consists of a public offering in Germany to retail and institutional investors and a private placement to certain institutional and other eligible investors in various other jurisdictions. Curetis AG\'s existing shareholders have agreed to lock-up provisions for a period of 365 days of which the first 180 days is a hard-lock period during which the restrictions under the lock-up may not be waived by the Joint Bookrunners (acting on behalf of the Underwriters). The Company, its managing directors and Curetis AG\'s current and former employees have also agreed to lock-up provisions for a period of 365 days. The restrictions under the lock-up provisions applicable to the Company\'s managing directors and Curetis AG\'s current and former employees may not be waived during their term. All lock-up arrangements are subject to customary carve-outs. RBC Capital Markets acted as Sole Global Coordinator for the Offering. RBC Capital Markets and Bank Degroof Petercam together acted as Joint Bookrunners for the Offering. ICF Bank AG acted as Joint Lead Manager for the Offering. The Joint Bookrunners and the Joint Lead Manager together acted as Underwriters for the Offering. ICF Bank AG acted as Retail Coordinator for the Offering of Offer Shares to eligible retail investors in Germany. RBC Capital Markets will also be acting as Stabilisation Manager on behalf of the Underwriters. * On October 28, 2015, Curetis announced the launch of the Offering. * On October 14, 2015, Curetis announced its intention to launch an IPO and listing on Euronext in Amsterdam and Euronext in Brussels.
Therapeutic area: Diagnostic
